<DOC>
	<DOC>NCT01568580</DOC>
	<brief_summary>The purpose of this study is to study the evaluation of efficacy and safety of GreenGene (Recombinant Factor VIII).</brief_summary>
	<brief_title>Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Hemophilia A patients at least 12 years of age At least 150 treatment exposuredays to previous FVIII products FVIII≤2% at screening or diagnosis (FVIII≤1% for PK study) CD4 Lympocyte cell count&gt;400/㎕ Patients willing to cooperate for the study Patient's or legal guardian's consent to participate in the study FVIII inhibitor(neutralizing antibody to FVIII)≥0.6 Bethesda Units Coagulation disorders other than hemophilia A (e.g. Idiopathic Thrombocytopenic Purpura, von Willebrand Disease) Platelet count≤100,000㎣ Subjects with clinical evidence of symptomatic HIV disease regardless of HIVseroposive/seronegative Subjects with rFVIII antibody, mouse IgG antibody, or CHO antibody Creatinine levels more than 2 times of reference rage, GOT and GPT levels more than 3 times of reference range, diabetes mellitus or other metabolic disorder Subjects with diastolic blood pressure≥100mmHg not controlled with antihypertensive medications Anemia(hemoglobin&lt;12g/dL) Subjects with severe or lifethreatening bleeding just before entry into the trial Subjects with a history of treatment failure due to formation of inhibitor to FVIII Subjects with a history of severe hypersensitive reactions to FVIII concentrate Subjects requiring premedication for FVIII infusion(e.g. antihistamines, etc)</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Factor VIII</keyword>
	<keyword>Recombinant</keyword>
</DOC>